Literature DB >> 944267

Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene.

J D McDermed, G M McKenzie, H S Freeman.   

Abstract

In an effort to identify further the structural requirements for central dopamine receptor agonists, some monohydroxyl analogs of the known agonist 5,6-dihydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene were synthesized. They were examined for production of emesis in dogs and stereotyped behavior in rats. The most potent was 5-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene, which was more potent than apomorphine but less so than the dihydroxyl analog. The two enantiomers of the monohydroxyl analog were synthesized by conventional methods from an optically active intermediate, 2-benzylamino-5-methoxy-1,2,3,4-tetrahydronaphthalene. The resolution of this amine was performed with the aid of mandelic acid. Dopaminergic activity was found to be confined to the levo enantiomer. Requirements for both substitution and chirality in the tetralines were found to correspond closely to those known for the dopaminergic aporphines.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 944267     DOI: 10.1021/jm00226a021

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.

Authors:  Dennis A Brown; Prashant S Kharkar; Ingrid Parrington; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

2.  (+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors.

Authors:  K Svensson; S Hjorth; D Clark; A Carlsson; H Wikström; B Andersson; D Sanchez; A M Johansson; L E Arvidsson; U Hacksell
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

Review 3.  Revision of the classical dopamine D2 agonist pharmacophore based on an integrated medicinal chemistry, homology modelling and computational docking approach.

Authors:  N Krogsgaard-Larsen; K Harpsøe; J Kehler; C T Christoffersen; P Brøsen; T Balle
Journal:  Neurochem Res       Date:  2014-07-24       Impact factor: 3.996

4.  Characterization of binding sites for [125I]R(+)trans-7-OH-PIPAT in rat brain.

Authors:  M P Kung; S Chumpradit; D Frederick; S Garner; K D Burris; P B Molinoff; H F Kung
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

5.  A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.

Authors:  M G Feenstra; C Sumners; J H Goedemoed; J B de Vries; H Rollema; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

6.  Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.

Authors:  K Fuxe; L F Agnati; C Köhler; D Kuonen; S O Ogren; K Andersson; T Hökfelt
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Release of radiolabeled dopamine, p-tyramine, and m-tyramine from rat striatal slices by some aminotetralins.

Authors:  L E Dyck
Journal:  Neurochem Res       Date:  1981-04       Impact factor: 3.996

8.  Effect of 8-hydroxy-2-(di-n-propylamino) tetralin on rat prolactin secretion.

Authors:  M Simonovic; G A Gudelsky; H Y Meltzer
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

9.  Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat.

Authors:  C T Dourish; P H Hutson; G Curzon
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Effect of non-catecholic 2-aminotetralin derivatives on dopamine metabolism in the rat striatum.

Authors:  M G Feenstra; H Rollema; D Dijkstra; C J Grol; A S Horn; B H Westerink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.